Facebook event page | Hashtags: #WorldDentalCongress & #FDI2017Madrid
cabecera

Intranasal tetracaine plus oxymetazoline

Elliott Hersh (USA)

Time: 10:30 - 11:30
Room: DALI (PV5)
Language: English
Chair(s): Guillermo Roser (Spain)
CERP: 1

Learning Objectives

  • > Identify the nerves consistently anaesthetized with intranasal tetracaine/oxymetazoline
  • Discuss the success rate of this novel formulation in carrying out routine restorative dentistry procedures
  • > Identify common side effects of intranasal tetracaine/oxymetazoline that have been illustrated in clinical trials
  • > Discuss future studies that need to be performed to expand the indication of this needleless drug delivery system

Abstract

The discomfort induced by local anaesthetic injections is often the most painful or only painful portion of many routine dental procedures. On June 29, 2016, an intranasal formulation of 3% tetracaine plus 0.05% oxymetazoline was granted United States FDA approval in providing local anaesthesia when performing a single restorative dental procedure in maxillary premolar, canine and incisor teeth. This presentation will review the safety and efficacy studies of this needleless local anaesthesia formulation. Future research that is either on-going, or needed to further expand this drug’s indications, will also be discussed.

Next Event

FDI 2017
29 August - 1 Septembre 2017
Madrid, Spain

Technical Secretariat

logoGPBlanco  Marià Cubí, 4 | 08006 | Barcelona
  +34 932.388.777
  +34 932.387.488
  This email address is being protected from spambots. You need JavaScript enabled to view it.

Stay Connected on: